Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TriLink BioTechnologies, Inc. Announces License Agreement with LI-COR Biosciences

Published: Friday, October 19, 2012
Last Updated: Friday, October 19, 2012
Bookmark and Share
TriLink BioTechnologies Inc. (TriLink) announced that it has recently signed a licensing agreement with LI-COR® Biosciences to custom label oligonucleotides, nucleotides, and nucleosides with IRDye® near-infrared dyes.

"This offers our customers a product option that will be more specific to their research, while being based on the IRDye near-infrared dye technology they have grown to trust," says Jim Wiley, LI-COR senior strategic marketing manager. "TriLink has established itself as an expert in the field of modified nucleic acids and we're certain our customers will benefit from this agreement."

LI-COR offers IRDye near-infrared dye technology that delivers enhanced sensitivity due to low background autofluorescence in the near-infrared region and, therefore, higher signal to noise ratios. IRDye near-infrared dyes have absorption and emission wavelengths in the near-infrared spectrum, between 650 nm and 800 nm.

"As experts in modified nucleic acid chemistry and leaders in dye labeling nucleoside triphosphates and oligonucleotides, we are continually expanding our portfolio of available modifications," says Richard Hogrefe, Ph.D., TriLink president and CEO. "The innovative LI-COR infrared dye series, IRDye 650-800, is a perfect fit, opening new doors for our customers seeking enhanced signal-to-noise ratios and dynamic range in applications where autofluorescence is an issue."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TriLink BioTechnologies Announces Agreement with American Cleanroom Systems to build cGMP Facility
Agreement signed to build a 2,000 square foot pharmaceutical cGMP production suite within San Diego facility.
Thursday, October 24, 2013
TriLink Enters into Distribution Agreement with Astral Scientific
The agreement allows Astral to sell Trilink's modified nucleic acid products, including over 150 modified nucleotides, custom oligonucleotides and CleanAmp™ Hot Start PCR Products. The Australian based company supplies clinical diagnostic, life science and industrial markets.
Tuesday, November 15, 2011
TriLink Awarded Phase I Grant for a Second Hot Start PCR Project
TriLink Biotechnologies has received a $100,000 Phase I SBIR grant from the National Institutes of Health, to study an approach to PCR activation.
Tuesday, May 22, 2007
TriLink Awarded Phase II Grant for Start PCR Project
TriLink will optimize protocols for scale up and automated synthesis, in preparation for commercialization of the technology in early 2007.
Thursday, July 27, 2006
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!